<DOC>
	<DOCNO>NCT00574587</DOCNO>
	<brief_summary>Chemotherapy plus trastuzumab ( Herceptin ) standard treatment breast cancer . There circumstance treatment give prior surgery reduce size cancer imptove surgical outcome . In trial , oral drug call `` vorinostat '' give combination chemotherapy trastuzumab . Vorinostat histone deacetylase ( HDAC ) inhibitor approve U.S. Food Drug Administration treatment rare type cancer involve skin ( cutaneous T cell lymphoma ) , breast cancer . HDAC inhibitor work unsilencing tumor suppressor gene gene cancer cell repress ; gene turn back drug , lead death cancer cell . HDAC inhibitor vorinostat show enhance effect chemotherapy trastuzumab experimental system . The purpose trial determine optimal dose vorinostat use combination standard chemotherapy plus trastuzumab , determine whether vorinostat enhances effectiveness standard chemotherapy plus trastuzumab .</brief_summary>
	<brief_title>Trial Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel , Trastuzumab , Doxorubicin Cyclophasmide Weekly Basis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast associate following stage : IIB , IIIA , IIIB IIIC . Tumor must Her2/neu positive No prior chemotherapy , radiation definitive therapeutic surgery May receive investigational agent Uncontrolled intercurrent illness</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Vorinostat</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
</DOC>